We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
This morning, we see really terrific numbers on Q4 Productivity — the key to a strong economy outside employment levels, etc. It’s a first read, so subject to revisions in the future, but for now we’ll take it: +3.0% is half a percentage point higher than expected, and more than double the upwardly revised +1.4% the previous quarter. This is the best print in exactly a year.
To add to this good news, Q4 Unit Labor Costs came down 40 bps from expectations: +1.1%, nearly half of the previous quarter’s downwardly revised +2.0%, and the smallest month-over-month result since Q1 2021. We haven’t thrown around the term “Goldilocks” too much lately, but this morning, the shoe fits (to mix up fairy tale metaphors — you’re welcome).
Initial Jobless Claims also came down last week: 183K was 8K lower than expectations, and even lower than the downwardly revised 186K the previous week. We haven’t seen new jobless claims this low since April of last year — fairly remarkable considering the amount of layoffs we’ve seen, at least in the Tech sector, over the past month or two.
Continuing Claims sank, as well, to 1.655 million two weeks ago (Continuing Claims are reported a week in arrears from new claims) from a downwardly revised 1.67 million the previous week. Basically, anything below 2 million longer-term jobless claims can be considered a win for the labor market. And we are currently at historically low levels on long-term jobless claims, even with the aforesaid layoffs.
Of course, tomorrow’s nonfarm payroll report from the U.S. Bureau of Labor Statistics (BLS) will be the major guide for how American employment is holding up in our current economic climate. Expectations are for fewer than 200K new jobs created last month — and investors of late have kept one eye open for a downward surprise that has yet to manifest itself, again in light of recent layoffs announced.
Elsewhere, we saw earnings beats this morning from Big Pharma players Merck (MRK - Free Report) , Bristol Myers-Squibb (BMY - Free Report) and Eli Lilly (LLY - Free Report) , with only Lilly coming up short on the top-line. These figures follow Pfizer’s (PFE - Free Report) big quarter earlier this week, and they pre-date the big afternoon coming up this earnings season: Apple (AAPL - Free Report) , Amazon (AMZN - Free Report) and Alphabet (GOOGL - Free Report) all report results after today’s closing bell.
Image: Shutterstock
Goldilocks Econ Data Presides Over Pre-Market
Thursday, February 2nd, 2023
This morning, we see really terrific numbers on Q4 Productivity — the key to a strong economy outside employment levels, etc. It’s a first read, so subject to revisions in the future, but for now we’ll take it: +3.0% is half a percentage point higher than expected, and more than double the upwardly revised +1.4% the previous quarter. This is the best print in exactly a year.
To add to this good news, Q4 Unit Labor Costs came down 40 bps from expectations: +1.1%, nearly half of the previous quarter’s downwardly revised +2.0%, and the smallest month-over-month result since Q1 2021. We haven’t thrown around the term “Goldilocks” too much lately, but this morning, the shoe fits (to mix up fairy tale metaphors — you’re welcome).
Initial Jobless Claims also came down last week: 183K was 8K lower than expectations, and even lower than the downwardly revised 186K the previous week. We haven’t seen new jobless claims this low since April of last year — fairly remarkable considering the amount of layoffs we’ve seen, at least in the Tech sector, over the past month or two.
Continuing Claims sank, as well, to 1.655 million two weeks ago (Continuing Claims are reported a week in arrears from new claims) from a downwardly revised 1.67 million the previous week. Basically, anything below 2 million longer-term jobless claims can be considered a win for the labor market. And we are currently at historically low levels on long-term jobless claims, even with the aforesaid layoffs.
Of course, tomorrow’s nonfarm payroll report from the U.S. Bureau of Labor Statistics (BLS) will be the major guide for how American employment is holding up in our current economic climate. Expectations are for fewer than 200K new jobs created last month — and investors of late have kept one eye open for a downward surprise that has yet to manifest itself, again in light of recent layoffs announced.
Elsewhere, we saw earnings beats this morning from Big Pharma players Merck (MRK - Free Report) , Bristol Myers-Squibb (BMY - Free Report) and Eli Lilly (LLY - Free Report) , with only Lilly coming up short on the top-line. These figures follow Pfizer’s (PFE - Free Report) big quarter earlier this week, and they pre-date the big afternoon coming up this earnings season: Apple (AAPL - Free Report) , Amazon (AMZN - Free Report) and Alphabet (GOOGL - Free Report) all report results after today’s closing bell.
Pre-market futures were flat directly following this morning’s news items, but are now up across the board: the Dow has swung into the green during the writing of this column, +38 points, whixh is matched exactly by the S&P 500. The tech-heavy Nasdaq, already the big outperformer year-to-date, is +250 points at this hour.
For more on MRK’s earnings, click here.
For more on BMY’s earnings, click here.
For more on LLY’s earnings, click here.
Questions or comments about this article and/or its author? Click here>>